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ABSTRACT
AKT and its substrate BAD have been shown to promote prostate cancer cell survival. Agonists, such as carbachol, and hormones that increase 
intracellular calcium concentration can activate AKT leading to cancer cell survival. The LNCaP prostate cancer cells express the carbachol-
sensitive M3-subtype of G protein-coupled receptors that cause increases in intracellular calcium and activate the family of Ca
2þ/calmodulin-
dependent protein kinases (CaM Ks). One type of CaM Kinase, CaM Kinase Kinase (CaM KK), phosphorylates several substrates including AKT 
on threonine 308. AKT phosphorylation and activation enhances cell survival through phosphorylation of BAD protein and the subsequent 
blockade of caspase activation. Our goals were to examine the mechanism of carbachol activation of AKT and BAD in LNCaP prostate cancer 
cells and evaluate whether CaM KK may be mediating carbachol’s activation of AKT and cell survival. Our results suggest that carbachol 
treatment of LNCaP cells promoted cell survival through CaM KK and its phosphorylation of AKT. The bacterial toxin anisomycin triggered 
caspase-3 activation in LNCaP cells that was blocked by carbachol in a CaM KK- and AKT-dependent manner. AKT and BAD phosphorylation 
were blocked by the selective CaM KK inhibitor, STO-609, as well as siRNA directed against CaM KK. BAD phosphorylation was also blocked 
by treating cells with the AKT inhibitor, AKT-X, as well as siRNA to AKT. Additionally, epinephrine promoted LNCaP cell survival through 
activation of AKT that was insensitive to STO-609. Taken together these data suggest a survival role for CaM KK operating through AKT and 
BAD in LNCaP prostate cancer cells. 
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P rostate cancer is the second most common cause of deathamong men in the United States [Schwartz and Hanchette,
2006; Colli and Amling, 2008]. The cell signaling pathways that
regulate prostate cancer cell behaviors are an important area of
current cancer research. Several cellular molecules have been
implicated in promoting prostate cancer cell survival and metastasis
including p53, Bcl-xL, PI3-K, BAD, PKA, and the phosphatase PTEN
[Moul, 1999; Assinder et al., 2009]. PTEN has been characterized as a
tumor suppressor that is frequently mutated in prostate cancer
resulting in the activation of various cellular enzymes including
protein kinase B also known as AKT [Assinder et al., 2009]. AKT is
activated in numerous cells by various agonists and hormones
including insulin, epinephrine, epidermal growth factor, and
isoproterenol. AKT has been implicated in promoting cell survival
or anti-apoptotic (death) signals within certain cells including the
lymphnode carcinoma of the prostate (LNCaP) cell model system [de
Souza et al., 2009; Goc et al., 2011]. AKT can be phosphorylated on
threonine 308 and activated by several kinases including PDK1,
mTOR, CaM Kinase Kinase, and PKA [Yano et al., 1998; Chan et al.,
1999; Sastry et al., 2007; Assinder et al., 2009]. AKT has the ability
to phosphorylate numerous substrates involved in cell survival, such
as MDM2, BAD, and XIAP [Cheng et al., 2005, 2008]. Consequently,
the ability of a cell to carefully regulate AKT activity and its
downstream targets is imperative for managing whether the cell may
undergo apoptosis or survival.
AKT has been shown to promote cell survival through phos-
phorylation of the protein BAD in several cell types including
NG108 neuroblastoma and LNCaP cells [Yano et al., 1998; Sastry
et al., 2007]. The phosphorylation of BAD at serine 136 promotes its
binding to the cytoplasmic protein, 14-3-3, and BAD sequestration
away from mitochondria [Rapp et al., 2007]. BAD is a proapoptotic
molecule that enhances cell death when it binds to mitochondrial
Bcl-2 or Bcl-xL proteins and causes the release of cytochrome c.
Increases in cytoplasmic cytochrome c concentration promote the
activation of the cell death-inducing caspases including caspase-3
[Condorelli et al., 2001]. Caspase-3 and its downstream targets
directly and exponentially execute cellular apoptosis. Consequently,
BAD phosphorylation and association with 14-3-3 prevents the
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activation of caspases and may promote cell survival. Interestingly,
recently this has been shown that PKA activation of AKT in LNCaP
cells leads to their survival [Sastry et al., 2007]; however, the role of
intracellular calcium signalingmolecules upstream of AKT in LNCaP
cells has not been carefully evaluated.
Recent epidemiological data suggest that calcium may play an
important role in prostate cancer progression in certain populations
[Butler et al., 2010; Raimondi et al., 2010]. Hormones and agonists
(i.e., carbachol) that increase the concentration of intracellular
calcium can activate several intracellular molecules including
calmodulin, calmodulin-dependent protein kinases (CaM Kinases),
PKC, phospholipase A, and CalDAG-GEFs [Means, 2008; Stefanini
et al., 2009; van Rossum and Patterson, 2009]. The LNCaP cells
express an array of cellular receptors that may trigger cellular
growth, survival, and intracellular calcium signaling pathways. G
protein-coupled receptors (GPCRs) have been implicated in
activating AKT and also give rise to an increase of calcium inside
the cell [Rayford et al., 1997; Nagmani et al., 2003; Sastry et al.,
2007]. Specifically, the M3-subtype of GPCRs are expressed in
LNCaP cells and promote their growth in response to carbachol
treatment however the mechanism of carbachol- and calcium-
dependent signaling in LNCaP cells was not evaluated [Rayford
et al., 1997].
Intracellular calcium binds calmodulin and activates the family
of calcium/CaM Kinases that includes CaM KII (multiple isoforms)
and CaM KKa/b isoforms as well as its downstream targets CaM KI
(multiple isoforms) and the predominantly nuclear CaM KIV [Means,
2008; Wayman et al., 2008]. In addition, CaM KK can directly
phosphorylate and activate AKT through phosphorylation of
threonine 308 and AMPK at threonine 172 [Yano et al., 1998;
Hurley et al., 2005]. CaM KK activation of AKT has been implicated
in neuronal survival [Yano et al., 1998]. CaM KK signaling through
CaM KI has recently been shown to promote ERK activation and
breast cancer cell growth downstream of carbachol and estrogen
signaling [Schmitt et al., 2010]. Interestingly, contemporary work by
Frigo et al. [2011] has demonstrated that CaMKK is highly expressed
in prostate cancer cells and mediates androgen-stimulated LNCaP
cell migration through AMPK; however, the role for CaM KK
activation of AKT and LNCaP survival was not examined.
Given that the activation of AKT and its subsequent modulation
of downstream targets promotes cancer cell survival we examined, if
CaM Kinases, specifically CaM KK, regulates AKT activation in
LNCaP cells. Additionally, we sought to evaluate if CaM KK-AKT
activation downstream of calcium signaling controls BAD phos-
phorylation and caspase-3 activity in prostate cancer cells. To
accomplish these goals we utilized molecular, biochemical, and
pharmacological approaches to elucidate the important role for CaM
Kinases and AKT inside of LNCaP cells. Our data suggest that a novel
calcium signaling pathway exists in LNCaP cells and may provide
valuable cellular targets in prostate cancer disease treatment.
MATERIALS AND METHODS
MATERIALS
The following materials were purchased from Sigma–Aldrich;
carbachol, epinephrine, EGTA, and MTT reagent. KN-93, STO-609,
anisomycin, ionomycin, and 4-DAMP were from Tocris Biosciences.
The AKT inhibitor, AKT-X was from EMD Biosciences. The
chemiluminescent reagent that is a substrate for HRP was purchased
from Thermo Scientific (Pierce Biotechnology). Antibodies that bind
to phosphorylated AKT at Threonine 308 (p308) and Serine 473
(p473), phosphorylated BAD at Ser136 (pBAD), cleaved caspase-3
(Asp175), and b-actin were purchased from Cell Signaling
Technology. Antibodies that recognize CaM KKa, CaM KIg, CaM
KIa, phospho-CaM KI, AKT, BAD, HA as well as HRP-conjugated
secondary antibodies were purchased from Santa Cruz Biotechnol-
ogy. siRNAs directed against human AKT1/2 (sc-43609), human
CaM KIa (sc-38947), or scrambled control siRNAs were also
purchased Santa Cruz Biotechnology. The caspase-3 colorimetric
assay was purchased from Biovision Inc. The Guava Nexin Reagent
was purchased from Guava Technologies/Millipore (Hayward, CA).
CELL CULTURE
The LNCaP cells were a generous gift from Dr. Thomasz Beer at
OHSU (Portland, OR). LNCaP cells were cultured in RPMI and 5%CO2
according to ATCC guidelines. LNCaP cells were serum-starved in
RPMI overnight, pretreated as indicated, and then stimulated for
Western blotting, caspase activity, or the cell survival assay. Cells
were pretreated with the following inhibitors for 30min prior to
stimulation, 4-DAMP (2mM), KN-93 (5mM), EGTA (2.5mM), AKT-X
(5mM), or STO-609 (5mM), and then treated with ionomycin (1mM),
carbachol (10mM), or epinephrine (100 nM) as indicated. Aniso-
mycin (5mM) was incubated with cells for 6 h prior to stimulation as
indicated.
WESTERN BLOTTING AND IMMUNOPRECIPITATION
LNCaP cells were stimulated, lysed, and equivalent protein amounts
were blotted onto PVDF membranes and examined by Western
blotting. Prior to Western blotting, protein concentrations were
determined using the Bradford protein assay and amicroplate reader
(Bio-Rad Model 680). PVDF membranes were probed using the
indicated antibodies, scanned, and densitized using a molecular
imaging system (Kodak Image Station, 2000R) and evaluated for
significant differences among treatments. In all cases, phosphory-
lated or cleaved protein levels were normalized to total protein levels
and controls for final analysis and presented as fold over basal. For
transfection experiments, 500mg of whole-cell lysates were
precipitated overnight with the indicated antibodies at 48.
Precipitates were washed 2" in ice-cold lysis buffer, run on
SDS–PAGE gels, and analyzed by Western blotting.
TRANSFECTION EXPERIMENTS
LNCaP cells were co-transfected with 2.5mg HA-AKT along with
2.5mg shCaMKKa, 2.5mg shCaMKIg (all three were a generous gift
from Dr. Tom Soderling at the Vollum Institute, OHSU), siRNA
directed against CaM KIa (Santa Cruz Biotechnology), scrambled
control siRNA, or the control pcDNA3 plasmid as indicated. The
shCaMKIg and shCaM KKa sequences and vectors have been
previously described in detail [Wayman et al., 2006; Saneyoshi et al.,
2008; Wayman et al., 2011]. LNCaP cells were also transfected with
siRNA directed against CaM KIa, AKT1/2, or scrambled control
siRNAs according to the manufacturer’s guidelines (Santa Cruz
Biotechnology). Transfections were done at approximately 50–60%
confluence for #6 h using Lipofectamine 2000 (Invitrogen,
Corporation). Following transfection, cell media was replaced
with complete media and cells were allowed to recover #24 h.
Transfected cells were then serum-starved overnight prior to
treatment with carbachol (10mM), lysis, and Western blot analysis.
CASPASE-3 ASSAY
Caspase-3 activity was examined from LNCaP cell extracts based on
its ability to recognize and cleave its substrate, DEVD-pNA. Caspase
activity was assayed according to the manufacturer’s guidelines
(BioVision Research Products). Equivalent LNCaP cell numbers were
placed on 96-well plates in RPMI, induced into quiescence for 24 h,
and pretreated with inhibitors for 30min and then anisomycin,
carbachol, epinephrine, or the indicated combinations for 6 h, lysed,
and equivalent protein amounts (200mg) were incubated with
DEVD-pNA substrate for 2 h according to the manufacturer’s
guidelines. Samples were then read using a microplate reader (Bio-
Rad Model 680) with the 405 nm filter. Caspase-3 activity was
normalized to untreated control cells and presented as fold over
basal.
CELL SURVIVAL ASSAY
Equivalent LNCaP cell numbers were placed on 96-well plates in
RPMI, induced into quiescence for 24 h, and pretreated with
inhibitors for 30min and then anisomycin, carbachol, epinephrine,
or the indicated combination for 6 h. Twenty microliters of MTT
Reagent (Thiazolyl blue tetrazolium bromide) was added to the cells
and incubated for 2 h at 378C. The MTT-treated cells were carefully
homogenized by the addition of SDS-containing detergent and the
plate was read using a microplate reader (Bio-Rad Model 680) with
the 595 and 655 nm filters.
APOPTOSIS ASSAY
Equivalent LNCaP cell numbers were placed on 3.5 cm plates in
RPMI, induced into quiescence for 24 h, and pretreated with
inhibitors for 30min and then anisomycin, carbachol, epinephrine,
or the indicated combination for 6 h. Approximately 300,000 cells
were analyzed for each treatment from four independent experi-
ments. Following the treatments, LNCaP cells were mechanically
dislodged and incubated with Guava Nexin Reagent (that contains
dye-labeled Annexin V and 7-AAD) in the dark according to the
manufacturer’s guidelines (Guava Technologies/Millipore). Cells
were then placed into 96-well plates and immediately read and
analyzed using a Guava Flow Cytometry System (Guava Technolo-
gies). Cellular apoptosis was determined based on dye-labeled
Annexin V cell surface binding to LNCaPs and presented as the
percentage of apoptotic (Annexin V positive) over non-apoptotic
(Annexin V negative). The apoptosis assay was performed in the
laboratory of Dr. Brian Druker in the Knight Cancer Institute at
OHSU.
STATISTICS
To determine if significant differences exist among treatments in our
system statistical analysis was performed on quantified data. Data
from each treatment was averaged, the standard error was
determined, and statistical significance (P-value) analyzed using
a Student’s t-test. In all cases, ‘‘$’’ and ‘‘$$’’ represented as P-value
of %0.05 and %0.01, respectively.
RESULTS
CARBACHOL BLOCKS APOPTOSIS IN LNCAP CELLS VIA CAM KK
LNCaP cells express muscarinic acetylcholine receptors that increase
intracellular calcium concentrations and promote cell growth upon
carbachol stimulation [Rayford et al., 1997]. Carbachol and calcium-
elevating agents are also sufficient to activate CaM Kinases and AKT
that in turn promote cell growth and survival [Yano et al., 1998;
Jimenez and Montiel, 2005; Schmitt et al., 2010]. To examine the
physiological significance of calcium and CaMKinases in promoting
LNCaP cell survival, we utilized the MTT assay to quantify cell
viability under various stimulatory conditions. Furthermore, we
utilized the toxin anisomycin at a dose and duration that has
previously been shown to promote caspase-3 activation and prostate
cancer cell death [Curtin and Cotter, 2002; Sah et al., 2003; Hori
et al., 2008]. As can be seen in Figure 1A, treatment of LNCaPs with
anisomycin triggered a substantial drop in cell survival that was
reversed by stimulation with carbachol. To examine the role for
calcium and CaM Kinases in LNCaP survival we began by using the
compound EGTA that functions as a chelator of calcium ions and
KN-93 that selectively inhibits the CaM Kinase family of enzymes.
Carbachol’s ability to promote survival was significantly blocked by
EGTA, and the broad CaM Kinase inhibitor, KN-93 (Fig. 1A). To
evaluate which CaM Kinase may be mediating carbachol’s effects we
used the selective inhibitor of CaM KK, STO-609, as well as the AKT
inhibitor AKT-X. Carbachol’s ability to enhance cell survival was
blocked by both STO-609 and AKT-X (Fig. 1B). Epinephrine
promotes PKA-dependent AKT phosphorylation and LNCaP cell
survival [Sastry et al., 2007], therefore, to confirm the specificity of
the STO-609 compound in our system, we stimulated cells with
epinephrine in the presence or absence of STO-609. Epinephrine
treatment of LNCaPs also promoted cell survival and reversed
anisomycin’s toxic effects (Fig. 1C). Interestingly, STO-609 did not
affect epinephrine signaling however inhibition of AKT with AKT-X
blocked epinephrine’s survival effect on LNCaPs (Fig. 1C).
Cellular apoptosis can also be evaluated based on the ability of
apoptotic cells to bind fluorescently labeled Annexin V on their
plasma membrane followed by flow cytometry analysis. To directly
assess the ability of anisomycin to trigger cellular apoptosis LNCaPs
were treated as in Figure 1 and then incubated with Annexin V
(Guava Nexin Reagent) and analyzed by flow cytometry on a Guava
Flow System. Consistent with the data from Figure 1, anisomycin
potently enhanced LNCaP apoptosis that was blocked by carbachol
treatment of cells (Fig. 2A). Carbachol’s survival effects were
significantly inhibited by pretreatment with EGTA and KN-93
(Fig. 2A) as well as STO-609 and AKT-X (Fig. 2B). To further confirm
the protective effects of epinephrine and the selectivity of STO-609
in our system, LNCaP cells were stimulated with epinephrine and
analyzed for Annexin V binding by flow cytometry. Epinephrine
inhibited anisomycin-induced apoptosis in a manner that was AKT-
dependent (blocked by AKT-X) but insensitive to STO-609 (Fig. 2C).
Taken together the above results suggest that carbachol specifically
utilizes calcium, CaM KK, and AKT to promote LNCaP survival and
block apoptosis. In addition, the hormone epinephrine also promotes
cell survival in a CaM KK-independent manner but appears to utilize
AKT.
CARBACHOL INHIBITS CASPASE-3 ACTIVITY
The caspase family of enzymes regulate cell survival and provide an
important role in controlling the fate of a cell. Caspases can be
activated through a variety of means including cell stresses that
cause BAD association with mitochondria and subsequent release of
cytochrome c from the organelle [Condorelli et al., 2001]. Caspase-3
activity is an established means to promote cell death therefore we
evaluated the ability of carbachol and CaM KK to regulate caspase-3
activity in anisomycin-treated LNCaP cells. We utilized the toxin
anisomycin at a dose and duration similar to Figures 1 and 2.
Fig. 1. Carbachol promotes LNCaP survival through CaM KK and AKT. A:
Calcium and CaM Kinases mediate carbachol-stimulated cell survival. LNCaP
cells received no pretreatment or were pretreated with the CaM Kinase
inhibitor KN-93 (5mM) or the calcium chelator EGTA (2.5mM) as indicated
and then with anisomycin (5mM), carbachol (10mM), or the combination for
6 h. In all figures ‘‘C’’ represents the control non-stimulated cells. Cell survival
was then analyzed using the MTT assay as described in the Materials and
Methods Section (N¼ 4, 'SE, $$P% 0.01). B: STO-609 and AKT-X block
calcium-stimulated cell survival. LNCaP cells received no pretreatment or
were pretreated with the CaM KK inhibitor, STO-609 (5mM) or the AKT
inhibitor, AKT-X (5mM), and then stimulated similarly to panel A and analyzed
with the MTT assay (N¼ 4, 'SE). C: AKT but not CaM KK regulates epineph-
rine-stimulated cell survival. LNCaP cells received no pretreatment or were
pretreated with STO-609 (5mM) or AKT-X (5mM), and then stimulated with
anisomycin (5mM), epinephrine (100mM), or the combination for 6 h and
analyzed with the MTT assay (N¼ 4, 'SE).
Fig. 2. Carbachol blocks apoptosis through CaM KK and AKT. A: Carbachol
inhibits apoptosis through calcium and CaM Kinases. LNCaP cells received no
pretreatment or were pretreated with EGTA (2.5mM) or KN-93 (5mM), and
then with anisomycin (5mM), carbachol (10mM), or the combination for 6 h.
Cells were then incubated with Guava Nexin Reagent (Annexin V) and analyzed
as described in the Materials and Methods Section. Cellular apoptosis was then
analyzed using flow cytometry with a Guava Flow System as described in the
Materials and Methods Section (N¼ 4, 'SE). B: CaM KK and AKT block
anisomycin-induced apoptosis. LNCaP cells received no pretreatment or
were pretreated with STO-609 (5mM) or AKT-X (5mM), and then stimulated
similarly to panel A and analyzed with the Guava System assay (N¼ 4,'SE). C:
Epinephrine inhibits apoptosis through AKT but not CaM KK. LNCaP cells
received no pretreatment or were pretreated with STO-609 (5mM) or AKT-X
(5mM), and then stimulated with anisomycin (5mM), epinephrine (100mM),
or the combination for 6 h, and analyzed with the Guava System assay
(N¼ 4, 'SE).
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Caspase-3 activity was quantified using PARP cleavage and as can
be seen in Figure 3A, the bacterial toxin, anisomycin, promotes a
fourfold increase in caspase-3 activity. Carbachol treatment of
LNCaP cells did not activate caspase-3 and significantly attenuated
anisomycin’s ability to promote caspase activity (Fig. 3A). To
determine if CaM KK and AKT mediate carbachol’s inhibitory effect
on caspase-3, cells were pretreated with either STO-609 or the AKT
compound, AKT-X in the presence or absence of anisomycin and
carbachol as indicated. Consistent with the previous data,
anisomycin promoted caspase-3 activity that was blocked by
Fig. 3. CaM KK and AKT mediate carbachol’s blockade of caspase-3 activity. A: Carbachol blocks caspase-3 activity in LNCaP cells. LNCaP cells received no pretreatment or
were treated with anisomycin (5mM), carbachol, or the combination for 6 h. Caspase-3 activity was then analyzed as described in the Materials and Methods Section (N¼ 4,
'SE). B: Carbachol inhibits caspase-3 activity through CaM KK and AKT. LNCaP cells received no pretreatment or were pretreated with STO-609 (5mM) or AKT-X (5mM), and
then incubated with anisomycin (5mM), carbachol, or the combination for 6 h as in panel A. Caspase-3 activity was then analyzed (N¼ 4, 'SE). C: Carbachol blocks caspase-3
activation and cleavage. LNCaP cells were treated identically to panel B and endogenous cleaved caspase-3 was measured by Western blotting and the bands were densitized,
normalized to total actin, and quantitated (N¼ 4, 'SE). D: Epinephrine blocks caspase activation independent of CaM KK. LNCaP cells received no pretreatment or were
pretreated with STO-609 (5mM), and then incubated with anisomycin (5mM), epinephrine (100 nM), or the combination for 6 h. Caspase-3 activity was then analyzed (N¼ 4,
'SE). E: Epinephrine prevents caspase-3 activation and cleavage. LNCaP cells were treated identically to panel D and endogenous cleaved caspase-3 was measured by Western
blotting and the bands were densitized, normalized to total actin, and quantitated (N¼ 4, 'SE, $P% 0.05).
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carbachol; however, both STO-609 and AKT-X reversed carbachol’s
inhibitory effects on caspase-3 activity (Fig. 3B). As an additional
means to directly evaluate caspase-3 activity in our system, we
evaluated the cleaved and active form of caspase-3 in response to
anisomycin treatment. The immunoblots presented in Figure 3C
demonstrate that anisomycin promotes caspase-3 activation that is
blocked by carbachol treatment of cells. Similar to the preceding
data, carbachol’s inhibition of caspase activity was inhibited by
either STO-609 or AKT-X (Fig. 3C). Epinephrine promotes LNCaP
cell survival and consistent with these data, it also blocked the
ability of anisomycin to promote caspase-3 activation (Fig. 3D). To
confirm the selectivity of STO-609 in our system, epinephrine-
treated cells were also evaluated with the CaM KK inhibitor.
Epinephrine was capable of blocking caspase-3 activity in the
presence of STO-609 (Fig. 3D). The epinephrine effect on caspase-3
activity was also evaluated by Western blotting for the active
form of caspase-3. Epinephrine treatment of LNCaPs inhibited
caspase-3 cleavage in a manner that was insensitive to STO-609
(Fig. 3E). Taken together, these results suggest that carbachol and
epinephrine treatment of LNCaPs block caspase-3 cleavage and
activity. Furthermore, these data also purport that CaM KK
specifically mediates carbachol’s effects on caspase activity in
our system.
CARBACHOL AND CAM KINASES REGULATE AKT ACTIVITY
LNCaP cells express endogenous muscarinic receptors and carbachol
may work through the M3-subtype muscarinic receptor to activate
CaM Kinases in cancer cells [Rayford et al., 1997; Jimenez and
Montiel, 2005; Schmitt et al., 2010]. CaM KK has been shown to
directly phosphorylate and activate the survival protein AKT
through its phosphorylation of threonine 308 [Yano et al.,
1998], therefore we sought to examine the ability of carbachol
to trigger AKT phosphorylation in LNCaP cells. The selective
M3-subtype muscarinic receptor antagonist, 4-DAMP, blocks
carbachol activation of CaM Kinases and is a useful tool for
evaluating carbachol signaling in cancer cells [Schmitt et al.,
2010]. Carbachol treatment of LNCaP cells triggered AKT
phosphorylation at both threonine 308 (p308) and serine 473
(p473) within 5min (Fig. 4A). AKT phosphorylation at both sites
was completely blocked by inhibition of the M3 muscarinic receptor
with the 4-DAMP compound (Fig. 4A). To determine if calcium and
its downstream targets, the CaM Kinases, are involved in AKT
activation we pretreated LNCaP cells with either KN-93 or EGTA.
As can be seen in Figure 4B, carbachol stimulates AKT phos-
phorylation and full activation in a manner that is dependent upon
CaM Kinases and calcium as it is blocked by KN-93 and EGTA,
respectively. Previous research has shown that epinephrine triggers
the cAMP and PKA-dependent phosphorylation of AKT [Sastry
et al., 2007]. As an important control for the specificity of our
compounds we pretreated cells with either KN-93 or 4-DAMP and
then stimulated them with epinephrine. Epinephrine potently
stimulated AKT phosphorylation in a manner that was not affected
by either inhibitor (Fig. 4C).
Based on the observation that STO-609 blocked carbachol’s
survival effects and that CaM KK has previously been shown to
activate AKT through direct phosphorylation at threonine 308 we
evaluated LNCaP cells for the presence of endogenous CaM KK.
Western blotting of cellular extracts revealed the presence of CaM
KKa (alpha) in LNCaP cells (Fig. 4D). Given that LNCaP cells express
endogenous CaM KK and that KN-93 inhibits AKT activation we
wanted to determine if the selective inhibitor of CaM KK, STO-609,
affected carbachol’s activation of AKT. Carbachol induced a potent
phosphorylation and activation of AKT that was significantly
inhibited by treating cells with STO-609 (Fig. 4E). To evaluate
whether CaM KK mediates other calcium signaling pathways, cells
were also stimulated with ionomycin to increase intracellular
calcium following a pretreatment with STO-609. Ionomycin
promoted nearly a fourfold increase in AKT phosphorylation that
was dependent upon CaM KK as it was completely blocked by STO-
609 (Fig. 4F). Since epinephrine promotes PKA-dependent AKT
phosphorylation [Sastry et al., 2007], we next sought to confirm the
specificity of the STO-609 compound in our system by stimulating
cells with epinephrine in the presence or absence of STO-609.
Consistent with previous work, epinephrine enhanced AKT
phosphorylation at both sites however STO-609 had no effect on
epinephrine’s activation of AKT (Fig. 4G). Taken together these data
suggest that CaM KK mediates calcium-dependent phosphorylation
and activation of AKT in LNCaP cells.
CAM KK SPECIFICALLY MEDIATES AKT ACTIVATION
Since LNCaP cells express endogenous CaM KK and the phosphory-
lation of AKT is blocked by KN-93 and STO-609 we wanted to
directly evaluate if CaM KK is activated in our system as well as
inhibited by our compounds. CaM KI is directly phosphorylated and
activated by CaM KK on threonine 177 and functions as a means to
monitor CaM KK activity [Wayman et al., 2011]. Stimulation of
LNCaP cells with carbachol triggered a threefold increase in CaM KI
phosphorylation in a manner that was blocked by either KN-93 or
STO-609 suggesting that CaMKK is active in our system (Fig. 5A). To
determine whether CaM KK is required for AKT activation in LNCaP
cells, we transfected cells with shRNA plasmids designed to
knockdown expression of CaM KKa. The specificity of the CaM
Kinase shRNA plasmids have previously been described and
characterized in several cell types including cancer cells [Wayman
et al., 2006; Saneyoshi et al., 2008; Davare et al., 2010; Schmitt et al.,
2010; Wayman et al., 2011]. Transfection of LNCaPs with shCaM
KKa plasmids significantly reduced target protein expression,
whereas the control pcDNA3 plasmid had no effect (Fig. 5B). We
next sought to determine if carbachol’s stimulation of AKT
phosphorylation specifically utilized CaM KKa. As can be seen in
Figure 5C, carbachol treatment of pcDNA3/HA-AKT-transfected
cells triggered HA-AKT phosphorylation, an effect that was reversed
by blocking CaM KKa expression. CaM KK has numerous substrates
including AMPK, CaM KIV, AKT, and the various isoforms of CaM KI
including CaM KIg and CaM KIa. We have previously shown that
CaM KIg works downstream of CaM KKa in breast cancer cells to
promote their growth [Schmitt et al., 2010], whereas CaM KIa may
play a role in neuronal development [Saneyoshi et al., 2008];
therefore, we sought to examine if LNCaP cells express either CaM KI
isoform. As can be seen in Figure 5D, LNCaP cells appear to express
both isoforms of CaM KI and CaM KIg appears to be relatively more
abundant that CaM KIa in LNCaP cells. To control for the specificity
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of our shRNA to CaM KKa as well as ensure that CaM KK is not using
either CaM KI isoform to trigger AKT phosphorylation we ablated
the expression of CaM KIg and CaM KIa in LNCaP cells through
siRNA knockdown. Expression of pcDNA3 had no effect on CaM KIg
protein levels, however shCaM KIg expression potently inhibited
CaM KIg production in our system (Fig. 5E). To confirm that CaM
KKa does not utilize CaM KIg to activate AKT, we co-transfected
cells with the indicated constructs and then stimulated them with
Fig. 4. AKT activation in LNCaP cells. A: Carbachol activates AKT through muscarinic receptors in LNCaP cells. LNCaP cells were stimulated with carbachol (10mM) for 5min in
the presence or absence of the 4-DAMP (2mM) compound as described in the Materials and Methods Section. Cell lysates were analyzed and endogenous AKT activation was
measured byWestern blotting for phosphorylated-AKT (pAKT) at both threonine 308 (p308) and serine 473 (p473). In all figures ‘‘p308’’ and ‘‘p473’’ represent phosphorylation
at each site. The lower panel is a Western blot of total AKT proteins (AKT), demonstrating equal loading of AKT used for pAKT assays. Data are presented as fold AKT
phosphorylation over control (N¼ 8,'SE). B: AKT activation utilizes CaM Kinases and calcium. LNCaP cells were stimulated with carbachol for 5min or pretreated with the CaM
Kinase inhibitor KN-93 (5mM) or EGTA (2.5mM) as indicated and AKT activation was measured by Western blotting as in panel A (N¼ 4,'SE). C: KN-93 and 4-DAMP do not
effect epinephrine signaling in LNCaP cells. LNCaP cells received no pretreatment or were pretreated with KN-93 (5mM) or 4-DAMP (2mM), and then stimulated with
epinephrine (100 nM) for 5min. Endogenous AKT activation was analyzed by Western blotting (N¼ 4, 'SE). D: LNCaP cells express endogenous CaM KK alpha (a). Lysates of
NIH3T3, LNCaP, and MCF-7 cells were analyzed by Western blotting for endogenous CaM KKa. E: AKT activation by carbachol is CaM KK-dependent. LNCaP cells received no
pretreatment or were pretreated with STO-609 (5mM) and then stimulated with carbachol (10mM) for 5min as in panel A (N¼ 4, 'SE). F: Ionomycin activates AKT via CaM
KK. LNCaP cells received no pretreatment or were pretreated with STO-609 (5mM), and then stimulated with ionomycin (1mM) for 5min (N¼ 6, 'SE). G: Epinephrine
activation of AKT is CaM KK-independent. LNCaP cells received no pretreatment or were pretreated with STO-609 (5mM) and then stimulated with epinephrine (100 nM) for
5min (N¼ 6, 'SE).
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carbachol. Carbachol treatment of LNCaP cells promoted AKT
phosphorylation in the presence or absence of shCaM KIg (Fig. 5F).
Transfection of LNCaP cells with siRNA against CaM KIa also
blocked CaM KIa expression (Fig. 5G); however in cells
co-transfected with HA-AKT/siCaM KIa, AKT phosphorylation by
carbachol was not inhibited (Fig. 5H). Taken together, these results
suggest that carbachol’s phosphorylation of AKT on threonine 308
utilizes CaM KKa but not CaM KIg or CaM KIa.
CARBACHOL REGULATES THE APOPTOTIC PROTEIN BAD
The cellular protein, BAD, has several regulatory phosphorylation
sites that promote its association with 14-3-3, sequestration from
Fig. 5. AKT activation requires CaM KK but not CaM KI. A: Carbachol activates CaM KK in LNCaP cells. LNCaP cells received no pretreatment or were pretreated with KN-93
(5mM) or STO-609 (5mM), and then stimulated with carbachol (10mM) for 5min as in Figure 4. Cell lysates were analyzed and endogenous CaM KK activation was measured by
Western blotting for phosphorylated-CaM KI (pCaM KI) at threonine 177 (N¼ 4,'SE). B: shRNA directed against CaM KKa reduces its expression. LNCaP cells were transfected
with either pcDNA3 or shRNA as described in the Materials and Methods Section. Endogenous CaM KKa expression was measured by Western blotting and the bands were
densitized, normalized to total AKT, and quantitated. Data are presented as fold CaM KKa expression over AKT (N¼ 8, 'SE). C: Carbachol activation of AKT requires CaM KKa.
LNCaP cells were co-transfected with HA-AKT along with pcDNA3 or shCaM KKa, stimulated with carbachol (10mM) for 5min, and HA-AKT phosphorylation was analyzed as
indicated in the Materials and Methods Section (N¼ 6, 'SE, $$P% 0.01). D: LNCaP cells express endogenous CaM KI gamma (g) and CaM KI alpha (a). Lysates of LNCaP cells
were analyzed by Western blotting for endogenous CaM KI isoforms. The lower panel is a Western blot of total AKT proteins (AKT), demonstrating similar loading of AKT. E:
shRNA to CaM KIg blocks its expression in LNCaP cells. Cells were transfected as in panel A with either pcDNA3 or shRNA against CaM KIg. Endogenous CaM KIg expression was
analyzed and presented as fold over AKT (N¼ 8, 'SE). F: AKT activation is CaM KIg-independent in LNCaP cells. LNCaP cells were transfected as in panel E, stimulated with
carbachol (10mM) for 5min, and HA-AKT phosphorylation was analyzed (N¼ 6, 'SE). G: siCaM KIa blocks CaM KIa expression. LNCaP cells were transfected with scrambled
siRNA or siRNA directed against CaM KIa, CaM KIa expression was analyzed by Western blot, and normalized to total AKT protein (N¼ 8, 'SE). H: CaM KIa does not effect
carbachol activation of AKT. LNCaP cells were transfected as in panel G, stimulated with carbachol (10mM) for 5min, and HA-AKT phosphorylation was analyzed (N¼ 6,'SE).
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the mitochondria, and pro-survival role including on serine 136
[Datta et al., 1997; Pastorino et al., 1999; Tan et al., 2000; Zhou et al.,
2000; Li et al., 2004]. Interestingly, carbachol stimulation of LNCaP
cells enhanced BAD phosphorylation at serine 136 an effect that was
blocked by pretreatment with STO-609 or the AKT inhibitor, AKT-X
(Fig. 6A). Previous studies have shown that epinephrine utilizes PKA
to promote BAD phosphorylation and LNCaP survival [Sastry et al.,
2007]. To examine the specificity of STO-609 in our system we
treated cells with epinephrine in the presence or absence of the CaM
KK inhibitor. Consistent with previous work, epinephrine triggered
BAD phosphorylation, however CaM KK inhibition had no effect
on this pathway (Fig. 6B). To evaluate the requirement for AKT
operating downstream of carbachol in our pathway, we transfected
cells with either control scrambled siRNA or siAKT to inhibit AKT
expression. Expression of siAKT significantly blocked AKT expres-
sion (Fig. 6C) and carbachol-stimulated phosphorylation of BAD
(Fig. 6D). Taken together, these data suggest that carbachol
stimulates BAD phosphorylation in a CaM KK- and AKT-dependent
manner in LNCaP cells.
DISCUSSION
The cell signaling second messenger, calcium, plays a pivotal role in
a variety of cellular processes including growth, survival, metabo-
lism, contraction, and development [Borodinsky and Spitzer, 2006;
Endo, 2006]. In the present study, we have demonstrated that
calcium and CaM KK appear to promote LNCaP cell survival through
direct phosphorylation and activation of AKT and its downstream
target BAD (see model Fig. 7). The muscarinic receptor agonist,
carbachol, working through the M3 GPCR utilizes calcium and
CaM KK to enhance prostate cancer cell resistance to apoptosis.
LNCaP cells express endogenous CaM Kinases including the
CaM KKa (alpha) isoform. Using siRNA and pharmacological
inhibitors, our data reveal that CaM KK but not CaM KIg or CaM KIa
mediates calcium activation of AKT in our system (Fig. 7). AKT
regulation of BAD appears to prevent caspase-3 activation and
apoptosis in LNCaP cells. Our data also suggest that epinephrine
activates AKT and blocks apoptosis independent of CaM KK
signaling (Fig. 7).
Fig. 6. Carbachol stimulates BAD phosphorylation through CaM KK and AKT. A: STO-609 and AKT-X block carbachol activation of BAD. LNCaP cells received no pretreatment
or were pretreated with either STO-609 (5mM) or AKT-X (5mM), and then stimulated with carbachol (10mM) for 5min. Endogenous BAD phosphorylation was measured by
Western blotting for phosphorylated-BAD (pBAD). Phospho-BAD bands were densitized, normalized to BAD, and quantitated. Data are presented as fold BAD phosphorylation
over control (N¼ 6,'SE). B: Epinephrine activation of BAD in LNCaP cells is insensitive to STO-609. LNCaP cells were pretreated similarly to panel A and then stimulated with
epinephrine (100 nM) for 5min. Endogenous BAD phosphorylation was measured and analyzed as in panel A (N¼ 6, 'SE). C: siAKT blocks AKT expression. LNCaP cells were
transfected with scrambled siRNA or siRNA directed against AKT, AKT expression was analyzed by Western blot, and normalized to total BAD protein (N¼ 8, 'SE). D: siAKT
blocks carbachol-stimulated phosphorylation of BAD. LNCaP cells were transfected as in panel C and then stimulated with carbachol (10mM) for 5min. Endogenous BAD
phosphorylation was measured and analyzed (N¼ 8, 'SE).
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Several hormones and agonists have been shown to regulate
LNCaP cell signaling and their behaviors. For example, recent work
has demonstrated that vasoactive intestinal peptide (VIP) promotes
prostate cancer cell growth through activation of PKA, Rap1, and
ERK [Xie et al., 2007]. Similarly, PMA, interleukin-6 and Forskolin
enhance ERK activation and increase LNCaP cell proliferation
[Carson et al., 1999; Chen et al., 1999; Gioeli et al., 1999]. Indeed
ERK activation correlates with prostate cancer disease progression
[Gioeli et al., 1999] and previous work has suggested that calcium
elevating agents also increase ERK phosphorylation in LNCaP cells
[Chen et al., 1999], although the role for CaM Kinases in those
studies were not examined. Recent work from the Weber laboratory
has also elucidated how the hormone epinephrine working through
PKA and AKT promotes LNCaP cell survival [Sastry et al., 2007]. Our
results are consistent with these findings on epinephrine and expand
them also to include the calcium signaling agonists, carbachol and
ionomycin and may provide significant insight into our under-
standing of LNCaP cell survival. Based on our data, it appears as
though calcium requires CaM KK to directly activate AKT although
the ability of CaM KK to crosstalk with cAMP and PKA was not
specifically examined in our studies.
Human prostate cells express a myriad of receptor types including
those for estrogen, androgens, acetylcholine, a-/b-adrenergics, and
glucocorticoids [Nagmani et al., 2003; Sydorenko et al., 2003; Van
Coppenolle et al., 2004; Culig et al., 2005; Kung and Evans, 2009;
Fowler et al., 2010]. LNCaP cells have also been shown to possess a
number of functional endogenous receptors that may couple to
calcium signaling and consequently regulate their growth, survival,
and differentiation. Previous work has shown that androgens
promote LNCaP survival independent of PI3-K yet they may
simultaneously increase intracellular calcium concentration [Carson
et al., 1999]. Interestingly, CaM KK also appears to mediate
androgen-stimulated migration of prostate cancer cells [Frigo et al.,
2011]; however the role of AKT was not evaluated in those studies.
LNCaP cells also express multiple muscarinic GPCRs including
the M3-subtype that increase intracellular calcium levels and cell
proliferation in response to carbachol [Rayford et al., 1997]. To the
best of our knowledge, the ability of the M3 GPCR and calcium to
activate CaM Kinases in LNCaP cells has not been examined. Our
data now demonstrate a unique signaling pathway for the M3
receptor to activate CaM KK leading to its phosphorylation of AKT
and the subsequent enhancement of LNCaP survival. This novel
signaling mechanism through M3 receptors and CaM KK in LNCaPs
suggests that CaM KK inhibition may be a relevant therapeutic
target. In contrast, prostate cancer cell survival that is triggered by
adrenergic receptors may be blocked by PKA or AKT inhibitors but
not CaM KK compounds.
The CaM Kinase family of enzymes have an established role in
brain development and metabolism and recent work from numerous
groups has also begun to elucidate their involvement in cancer. CaM
KII appears to play a role in blood cell cancer differentiation and
proliferation [Si et al., 2007; Si and Collins, 2008]. CaM KII may
participate in prostate cancer cell signaling however LNCaP cells do
not express the alpha isoform of CaM KII [Mamaeva et al., 2009].
Interestingly, the broad compound inhibitor of all CaM Kinases, KN-
93, blocked prostate cancer cell proliferation and induced cell death
[Rokhlin et al., 2010], therefore the role for additional CaM Kinases
in prostate cancer is possible. CaM KK and its various substrates also
have an emerging role in breast, prostate, and neuronal cancer cells.
CaM KK directly activates and phosphorylates AKT on threonine 308
Fig. 7. Proposed model for PKA- and CaM KK-mediated LNCaP survival. Epinephrine treatment of LNCaP cells stimulates b-adrenergic receptors and an increase in
intracellular cAMP. cAMP activates PKA leading to the phosphorylation and activation AKT. Carbachol activates the M3-subtype of muscarinic receptors leading to increases in
intracellular calcium levels and the subsequent activation of CaM KK. CaM KK directly phosphorylates AKT on threonine 308 leading to full AKT activation and dual
phosphorylation. AKT phosphorylates the survival protein, BAD, leading to its association with 14-3-3 and subsequent blockade of caspase-3 activity and cellular apoptosis.
JOURNAL OF CELLULAR BIOCHEMISTRY AKT ACTIVATION IN LNCaP CELLS UTILIZES CaM KK 1523
to promote neuroblastoma cell survival, an observation that is
consistent with our data [Yano et al., 1998]. CaM KK working
through CaM KI also appears to mediate estrogen-stimulated
medulloblastoma cell migration [Davare et al., 2010]. In addition,
CaM KK and CaM KI promote breast cancer gene expression and cell
proliferation through ERK activation [Rodriguez-Mora et al., 2005;
Schmitt et al., 2010]. We knocked down CaMKIg and CaMKIa in our
system without inhibiting AKT phosphorylation that supports the
role for CaM KK control of AKT and BAD in LNCaP cells. CaM KK
also phosphorylates AMPK [Hurley et al., 2005] that has recently
been implicated in prostate cancer cell survival and appears to be
activated in human prostate cancers. Frigo et al. [2011] have also
shown that androgen treatment of LNCaP cells promotes a potent
upregulation of CaM KK expression as well as phosphorylation of
CaM KI and AMPK. CaM KK working through AMPK appears to
mediate prostate cancer cell migration and invasion but not
proliferation. Interestingly, the M3 receptor was recently reported to
promote CaM KK activation of AMPK and glucose uptake in muscle
cells [Merlin et al., 2010], although the role for AKT was not
evaluated. Based on the current data, it is intriguing to hypothesize
that calcium and CaM KK may be regulating two important parallel
pathways in prostate cancer cells; one pathway that operates
through AMPK to promote cell migration and a second pathway to
enhance cell survival. In future studies, it will be important to
determine the kinetics and localization of these unique signaling
cassettes as well as to evaluate the types of hormones and agonists
that trigger these calcium-mediated pathways.
The data presented in Figure 6 suggest that calcium and CaM KK
are capable of promoting LNCaP survival through the phosphory-
lation of BAD on serine 136. Consistent with other reports, both AKT
and BAD appear to contain some basal phosphorylation [Carson
et al., 1999; Sastry et al., 2007], that is, subsequently upregulated by
hormone treatment and BAD phosphorylation on serine 136 is
strongly correlated with cell survival [Datta et al., 1997]. BAD is
currently hypothesized to associate with the outer mitochondrial
membrane and modulate cytochrome c release and the subsequent
activation of the death inducing caspase enzymes (Fig. 7). Previous
studies have utilized the toxin anisomycin at a dose and duration
similar to that in our studies to trigger apoptosis in both prostate and
lymphoma cells [Curtin and Cotter, 2002; Sah et al., 2003; Hori et al.,
2008]. In our system both epinephrine and carbachol prevented
anisomysin-induced death at various timepoints and may utilize an
array of rapid antiapoptotic transcriptional mechanisms. For
example, testosterone has been shown to upregulate numerous
miRNAs that target calcium homeostasis and proliferation in
prostate cancer cells [Wang et al., 2011]. Calcium and CaM Kinases
may also target various prosurvival transcription factors and genes
including CREB, Elk-1, Wnts, C/EBP, Egr-1, and Hes-1 among others
[Mishra et al., 2005; Wayman et al., 2006; Mamaeva et al., 2009;
Schmitt et al., 2010]. In addition to BAD, AKT also regulates
numerous downstream survival targets most notably the Forkhead
box transcription factors and p53 [Cheng et al., 2005, 2008].
Interestingly, LNCaP cells in which intracellular calcium levels have
been increased may regulate CREB, ETS, transient receptor potential
channels (TRPCs), as well as several genes involved in cell
metabolism [Ben Aicha et al., 2007]. Evaluating the role of various
transcription factors and their targets downstream of CaM KK and
AKT in our system is an area of current interest.
The TRPCs are highly expressed in LNCaP cells and appear to play
an important role in their growth and migration. TRPCs are calcium-
permeable channels that are functionally responsive to phenyleph-
rine and carbachol in LNCaP cells [Sydorenko et al., 2003]. The TRPC
family of molecules include several members and TRPC1, TRPC3,
TRPV2, and TRPV6 have all been implicated in playing a role in
prostate cancer cell physiology and disease progression [Pigozzi
et al., 2006; Monet et al., 2010]. The role for TRPCs upstream of CaM
KK and CaM KI activity in hippocampal neurons has recently been
shown [Davare et al., 2009]; however we are unaware of a published
role for TRPC regulation of CaM Kinases in LNCaP cells. Similarly,
the calcium channel Orai1 and its regulator STIM may also
participate in intracellular calcium signaling events and appear to
block prostate cancer cell death [Flourakis et al., 2010]. The possible
role for TRPCs or Orai1 in promoting survival through CaM KK is
consistent with our data suggesting that extracellular calcium is
required for AKT activation downstream of carbachol stimulation of
LNCaP cells. Evaluating a functional link between these calcium
channels and CaM Kinases in cancer cells is an intriguing area of
research.
In summary, we have proposed a unique signaling pathway that
exists in LNCaP cells downstream of the GPCR agonist carbachol.
Epinephrine activated AKT and promoted LNCaP cell survival that
appears to be independent of CaM KK. Muscarinic receptor-
stimulation of LNCaP cells elevated intracellular calcium and
activated CaM KK leading to AKT and BAD phosphorylation as well
as survival of prostate cancer cells (Fig. 7). The results from our study
further support the importance of CaM Kinases in both health and
disease. In particular, CaM KK and its various downstream targets
including AKT, AMPK, and CaM KI appear to be significant enzymes
involved in cancer. The ubiquitous expression of these molecules
and the emerging role of CaM KK in cancer biology may provide
important therapeutic targets in the treatment of prostate cancer.
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